125I粒子近距离治疗在局部晚期腮腺腺样囊性癌的应用

目的单纯应用¹²⁵I放射性粒子组织间植入治疗局部晚期腮腺腺样囊性癌,评估疗效并分析相关预后因素,为局部晚期腮腺腺样囊性癌的治疗提供临床参考。方法回顾性纳入2007年8月至2018年1月于北京大学口腔医院接受单纯应用¹²⁵I放射性粒子植入治疗的局部晚期腮腺腺样囊性癌患者,分析其总生存率(OS)、无进展生存率(PFS)和局部控制率(LCR)及相关影响因素,并观察近、远期放射不良反应情况。结果本组病例共16例(cT4bN0M0),女性患者占多数(11/16,68.7%),中位年龄55.4岁。随访8~104个月(中位时间41.5个月),1、3、5年LCR分别为93.7%、80%、68.7%,1、3、5年OS分别为86.7%、72%、54%;1、3、5年PFS分别为74%、53%、18.9%。9例(56.2%)患者出现不同部位器官转移,以颅内转移、肺转移常见;其中6例术前伴有颅底骨质侵犯者出现多器官转移,肿瘤侵犯颈动脉是影响远处转移的危险因素(HR=12,P=0.045)。共有8例(8/16,50%)患者出现不同程度远期放射性不良反应。结论单纯应用¹²⁵I放射性粒子植入治疗局部晚期腮腺腺样囊性癌的5年局部控制率为68.7%,肿瘤侵犯颅底骨质、包绕颈动脉是其预后不佳与发生多器官远处转移的主要因素。     

125I放射性粒子治疗腮腺复发性腺样囊性癌的靶区设计及剂量学分析

目的 分析¹²⁵I放射性粒子单纯植入治疗腮腺区复发性腺样囊性癌的靶区设计方法及剂量学参数。方法 回顾性分析2005年1月至2019年10月北京大学口腔医院收治的行单纯¹²⁵I放射性粒子近距离植入治疗的25例复发性腮腺腺样囊性癌患者的靶区设计及剂量学参数。术前结合腺样囊性癌病理学特点对不同复发部位设计靶区范围,处方剂量为100~120 Gy,术后验证靶区范围与剂量学参数。随访统计局部控制情况及放疗相关不良反应。结果 25例患者复发部位分别为腮腺浅叶区10例,腮腺深叶区7例,颅底区及乳突颌后区复发各4例。中位植入粒子数量为59颗,粒子活度18.5~25.9 MBq,植入后验证所有患者均实现植入前靶区设计范围,D₉₀、V₁₀₀、V₁₅₀等剂量学参数与植入前相近,差异无统计学意义（P>0.05）。3年、5年局部控制率分别为81.5%和61.5%,不同部位的局部控制率差异无统计学意义（P>0.05）。结论 单纯应用¹²⁵I放射性粒子植入治疗腮腺区复发性腺样囊性癌,通过结合病理学特点及复发部位优化靶区设计,合理准确应用达到剂量学参数,可获得较好的局部控制。     

Unusual presentation of parotid gland adenoid cystic carcinoma : A case presentation and literature review

Adenoid cystic carcinoma (ACC) represents approximately 10% of all epithelial salivary neoplasms and most commonly involves the parotid gland.We report CT and MRI finding of a 38-year-old young man presented to our ENT department with 02 years history of an external auditory canal stenosis. Physical examination revealed bilateral parotid gland swelling with a complete stenosis of the left external auditory canal.Temporal bone contrast enhanced CT-SCAN revealed is an isodense enhancing mass measuring 4 cm involving posterior and inferior external auditory canal wall, and invading the superficial lobe of the homolateral parotid gland. No bone erosion was noted. MRI investigation has shown a tumor process highly suspicious of malignancy centered on the left EAC involving the superficial lobe of the homolateral parotid gland. Adenoid cystic carcinoma (ACC) of the parotid gland was the final diagnosis, after surgical biopsy and histopathological examination. The Pre-operative check-up demonstrated multiple round shape lung lesions suggestive of multiple metastases. Considering the metastatic stage of the tumor, a collegial decision to adopt a palliative treatment approach based on chemotherapy was taken by the multidisciplinary oncology board.     

Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis

Purpose

The aims of this study were to evaluate treatment responses and predictive factors for overall survival (OS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) treated with iodine-125 (¹²⁵I) brachytherapy.

Long-term local control of recurrent adenoid cystic carcinoma in the parotid gland with radiotherapy and intraarterial infusion chemotherapy

We report a case of postoperative recurrence of adenoid cystic carcinoma in the left parotid gland treated with radiotherapy and arterial infusion chemotherapy. A 52-year-old woman had a history of surgical resection for an adenoid cystic carcinoma arising from the left parotid gland 25 years before. Despite two reoperations for local recurrence after the initial surgery, she had a third local recurrence in the remnant of the left parotid gland. The patient was treated with a concurrent combination of radiotherapy (60 Gy/30F) and intraarterial infusion chemotherapy with carboplatin (750 mg/30 days) from which she obtained a complete response. The patient has remained free of local progression 54 months after treatment. Radiotherapy and arterial infusion chemotherapy is effective treatment for local recurrence of adenoid cystic carcinoma in the head and neck.     

CT引导下125Ⅰ粒子组织间植入治疗疼痛性淋巴结转移性腺癌

目的：探讨CT导向下125Ⅰ粒子组织间植入治疗疼痛性淋巴结转移性腺癌的疗效和安全性。方法：回顾性分析2010年4月～2010年9月在本院接受CT导向下125Ⅰ粒子组织间植入治疗的12例淋巴结转移性腺癌患者的病例资料。对比术前与术后患者的疼痛情况、肿瘤大小变化,并观察并发症情况,随访期2～6个月。结果：1例疼痛完全缓解,...     

Intracranial adenoid cystic carcinoma mimicking meningioma: report of two cases

Two cases of intracranial adenoid cystic carcinoma mimicking meningioma are reported. In one, MRI showed not only a homogeneously enhancing extra-axial tumour attached to the dura mater of the posterior cranial fossa, but also surrounding dural enhancement, the dural tail sign. In the second, CT demonstrated a well-demarcated enhancing extra-axial tumour, indistinguishable from a sphenoid ridge meningioma extending into the orbit. The neuroradiological features of intracranial adenoid cystic carcinoma may thus closely resemble those of meningioma.     

碘125粒子联合肝动脉化疗栓塞术治疗原发性肝癌合并门脉分支癌栓疗效分析

目的探讨碘125(~(125)I)粒子联合TACE治疗原发性肝癌合并门脉分支癌栓患者的临床疗效和安全性。方法收集中国医科大学附属第一医院自2013年1月至2015年12月经病理检查或影像学证实的诊断为原发性肝癌伴门脉分支癌栓的患者89例,分为治疗组(n=47)和对照组(n=41)。治疗组患者给予患者超声引导下行门脉癌栓125I粒子植入术及TACE治疗;对照组患者进行传统的TACE治疗。末次随访时间为2016年1月31日。主要研究终点是总体生存期(OS),次要终点包括:术后1个月的疗效评价及不良反应的评价。同时,对影响OS的因素进行分析。结果治疗组与对照组的OS分别为17.8个月和8.4个月(P<0.05)。通过COX模型分析发现,肝内病灶最大径是否>5 cm是影响OS的主要因素(P<0.01)。治疗组与对照组疾病有效率(RR)分别为89.5%、41.5%(P<0.05),疾病控制率(DCR)分别为94.7%、56.8%(P<0.05);两组患者主要不良反应为发热、恶心呕吐、肝区疼痛、转氨酶升高及白蛋白减低等,但不良反应发生率方面差异均无统计学意义(P>0.05)。结论125I粒子联合TACE在肝癌合并门脉分支癌栓患者的治疗中可以有效延长患者的生存期,值得进一步研究。     

125I粒子近距离照射在肿瘤治疗中的应用

125I的生物物理学特性适合近距离照射治疗,125I作为粒子源植入体内,目前在国外广泛用于各种恶性肿瘤的治疗,尤其是用于前列腺癌的治疗已相当成熟,取得了良好的疗效,但在治疗中还存在一定的问题.     

1.5T conventional MR-guided iodine-125 interstitial implants for hepatocellular carcinoma: feasibility and preliminary clinical experience

Purpose

To evaluate the feasibility and therapeutic efficacy of 1.5 T conventional MR-guided percutaneous interstitial implantation of I-125 radioactive seeds in patients with hepatocellular carcinoma (HCC).

Materials and methods

The institutional ethics committee approved this study. After imformed consent was obtained, twenty-three patients suffering from a total of 65 HCC lesions were treated with I-125 seed permanent interstitial implantation under the guidance of a 1.5 T conventional magnetic resonance imaging (MRI) system. The FSE T2WI, T1 FSPGR, FIESTA 2D, 3D Dyn T1WI sequences were used to guide an 18G MR-compatible needle inserted into the lesions to introduce the I-125 seeds. The response evaluation criteria in solid tumors (RECIST) were used to evaluate the curative effect.

Results

The needle and I-125 seed were seen clearly on MRI images. The final dose delivered to total decay was 173.46 ± 32.44 Gy (range, 110–270 Gy) as calculated by postoperative TPS. The complete response (CR) was seen in 22 lesions (33.8%), partial response (PR) in 24 lesions (36.9%), stable disease (SD) in 9 lesions (13.8%), and progressive disease (PD) in 10 lesions (15.4%). The post-operative alpha-fetoprotein (AFP) was decreased (t = 3.117, P = 0.005 < 0.05). Two patients were observed a small area of subcapsular bleeding that did not lead to any symptoms or clinical sequelae.

Conclusion

MR-guided I-125 implantation for HCC is technically feasible and effective.     

Comparison of outcomes using radiotherapy or brachytherapy after resection of primary adenoid cystic carcinoma in oral and maxillofacial regions

We wished to investigate the outcome of surgery combined with external-beam radiotherapy (EBRT) or brachytherapy (¹²⁵I seeds) for the treatment of primary adenoid cystic carcinoma (ACC) of the oral and maxillofacial region. Data of patients with primary ACC were reviewed retrospectively. Patients were divided into EBRT and brachytherapy groups. Wide tumor excision was done to achieve negative margins. Standard radiotherapy in the EBRT group was 60 Gy. A treatment-planning system was used to create implantation plans with a prescribed dose of 60–120 Gy and ¹²⁵I seeds were implanted postoperatively. Kaplan–Meier method and log-rank tests were used to analyze local control and survival. The median duration of followup was 66.1 and 46.8 months for the EBRT group and brachytherapy group, respectively. There was no significant difference in local control, control of metastasis to regional lymph nodes, or control of distant metastasis between the two groups. There was no significant difference in overall survival, disease-specific survival, or disease-free survival in the two groups at 3 years and 5 years. The prevalence of complications in the brachytherapy group was lower than that in the EBRT group. Both methods elicited good treatment effects, but the prevalence of adverse events was lower in the brachytherapy group.     

腮腺癌术后 125I 粒子组织间近距离治疗靶区确定方法的探讨

目的 探讨腮腺癌术后¹²⁵I粒子组织间近距离治疗靶区的确定方法。方法 2002年10月至2006年11月北京大学口腔医院的31例腮腺癌患者,男女比例14 ∶17,平均年龄38.2岁,肿瘤有包膜外浸润并与面神经关系密切(黏连或神经侵犯),采用保留面神经的肿瘤及腺体切除术,术后行¹²⁵I粒子组织间近距离治疗,匹配周缘剂量60 Gy。治疗前后行薄层螺旋CT扫描以制定治疗计划和质量验证,以腮腺周围骨性结构和肌组织为参照确定计划靶区和临床靶区,并比较治疗前后靶体积、靶区D₉₀值的差异,同时计算粒子植入后颌骨、中耳D₉₀值以及脊髓最大接受剂量。结果 ¹²⁵I粒子治疗前后靶体积、靶区D₉₀值差异无统计学意义,粒子植入后靶区D₉₀值均大于匹配周缘剂量。本组病例随访时间3~7年,未见肿瘤复发。结论 根据目前随访结果,采用本方法确定¹²⁵I粒子腮腺区组织间近距离治疗靶区,临床治疗效果满意。     

Adenoid cystic carcinoma: A case of rare breast cancer

Adenoid cystic carcinoma is a rare form of breast cancer accounting for 0.1%-1.0% of all mammary malignancies. It is characterized by an indolent clinical course and favorable prognosis, contrary to other breast cancers. Diagnostic mammogram and breast ultrasound play a pivotal role in the early detection and diagnosis of breast adenoid cystic carcinoma. Treatment may consist of lumpectomy and radiation therapy vs mastectomy alone. Even though rare, late disease recurrence and metastasis has been reported in the literature thus long-term surveillance is of utmost importance for these patients. We will review the literature and discuss the case of a 52-year-old female who presented with a palpable lump of the right breast, which was pathologically proven to be adenoid cystic carcinoma of the breast.     

125I籽源组织间照射在肿瘤治疗中的应用

125I的生物物理学特征适用于组织间放疗.在国外,用125I组织间照射治疗恶性肿瘤已有较广泛的应用,尤其是将125I籽源植入作为一种独特的方法用于治疗前列腺癌已经相当成熟,但是在其他肿瘤的治疗方面还处于研究阶段.     

气管腺样囊性癌的CT表现（附5例报告及文献复习）

目的探讨CT对气管腺样囊性癌的诊断价值。方法回顾性分析5例经手术和病理证实的气管支气管腺样囊性癌的CT表现,并复习国内外相关文献。结果气管腺样囊性癌在CT上兼有良恶性肿瘤的特征,CT轴位扫捕及其后处理技术的应用能准确地描述气管支气管腺样囊性癌的病变范围及气管腔内外的改变。结论CT对气管腺样囊性癌具有重要的诊断价值,应作为首选检查方法。     

The early evaluation of ultrasound-guided iodine-125 interstitial implants for high-risk hepatocellular carcinoma

IntroductionTo evaluate the feasibility and safety of ultrasound-guided iodine-125 interstitial implants for high-risk hepatocellular carcinoma.MethodsFrom October, 2016, to August, 2018, 49 patients suffering from a total of 66 hepatocellular carcinoma lesions were treated with ultrasound-guided iodine-125 interstitial implantation. Treatment planning system was applied to make preoperative plan. The response evaluation criteria in solid tumors were used to evaluate the curative effect. The evaluated outcomes included postoperative complications and complete disease control rate, 6-month disease-free survival, and 6-month overall survival.ResultsAll 49 patients underwent iodine-125 seed implantation successfully. Patients were followed up for 5 to 27.5 months. No patients developed serious complications and only 2 (4.1%) patients had slight pain. The complete response was seen in 21 lesions (31.8%), partial response in 26 lesions (39.4%), stable disease in eight lesions (12.1%), and progressive disease in 11 lesions (16.7%). The overall disease control rate was reached to 83.3%. The 6-month disease-free survival rate was 46.4% with a median disease-free survival time of 5.0 months. The 6-month overall survival rate was 83.6% with a median overall survival time of 15.0 months.ConclusionsIodine-125 interstitial implantation is a kind of safe and feasible treatment for high-risk hepatocellular carcinoma.     

125I植入对小鼠移植性实体瘤抑制效果

目的观察12I籽源组织间植入对小鼠移植性实体瘤的治疗效果.方法建立小鼠艾氏腹水瘤细胞移植性实体肿瘤模型.治疗组在肿瘤组织内平均植入4粒表面放射活性为8.14MBq的BT-125-Ⅰ型125I籽源,对照组植入4粒无放射活性的空心籽源.治疗28 d,记录小鼠存活率.处死存活的小鼠,测量残存肿瘤的体积、重量并计算肿瘤体积抑制率.对摘除的肿瘤组织进行常规病理切片检查,观察籽源对肿瘤组织的破坏程度和范围.结果治疗28 d,治疗组和对照组小鼠存活率分别为75%和50%;平均瘤重分别为(0.347±0.25)g,(5.162±1.75)g(t=6.164,P＜0.05);肿瘤平均体积分别为(175.9±147.9)mm3,(3974.1±1507.7)mm3(t=5.618,P＜0.05),肿瘤体积抑制率为95.6%.常规病理切片结果显示,125I籽源周围0～3 mm范围内肿瘤细胞病理变化由凝固坏死向外逐渐减弱为变性坏死;空心籽源周边区域仅有机械刺激导致的轻微水肿和纤维化.结论125I籽源组织间植入对小鼠实体肿瘤具有显著的治疗效果.     

125I放射性粒子治疗复发性腮腺癌24例临床分析

目的 探讨应用¹²⁵I放射性粒子组织间植入近距离放疗在腮腺区复发恶性肿瘤的临床应用及疗效。方法 回顾性分析2006年至2013年,就诊于北京大学口腔医院,经放射性¹²⁵I粒子组织间植入治疗的24例复发腮腺腺源性恶性肿瘤患者的临床资料,所有患者均为临床Ⅳ期。定期随访,观察并分析局部控制率,生存率及不良反应。结果 24例复发肿瘤患者,随访时间4至59个月。6例局部控制失败,10例患者死亡。患者1年、3年生存率分别为74.8%和39.3%,1年、3年无进展生存率分别为74.8%和31.5%,1年、3年局部控制率分别为82.0%和69.4%。无3级以上放射性损伤。结论 单纯放射性¹²⁵I粒子组织间植入治疗,对于无法手术切除的复发腮腺恶性肿瘤患者,为可选治疗方式,局部控制率较好。